549 related articles for article (PubMed ID: 26416247)
1. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
[TBL] [Abstract][Full Text] [Related]
2. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
3. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.
Zhou Z; Liu Y; Ma M; Chang L
Biomed Pharmacother; 2017 Dec; 96():98-103. PubMed ID: 28965013
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.
Cho SW; Kim YA; Sun HJ; Ahn HY; Lee EK; Yi KH; Oh BC; Park DJ; Cho BY; Park YJ
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1641-9. PubMed ID: 24848709
[TBL] [Abstract][Full Text] [Related]
6. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
[TBL] [Abstract][Full Text] [Related]
7. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S
Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517
[TBL] [Abstract][Full Text] [Related]
8. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling.
Zhang X; Li M; Zuo K; Li D; Ye M; Ding L; Cai H; Fu D; Fan Y; Lv Z
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1305-13. PubMed ID: 23796566
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
Wen D; Liao T; Ma B; Qu N; Shi RL; Lu ZW; Wang YL; Wei WJ; Ji QH
Cancer Med; 2018 Feb; 7(2):285-296. PubMed ID: 29341469
[TBL] [Abstract][Full Text] [Related]
10. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
11. Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation.
Cho NL; Lin CI; Whang EE; Carothers AM; Moore FD; Ruan DT
Thyroid; 2010 Jun; 20(6):615-22. PubMed ID: 20470206
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.
Li JY; Han C; Zheng LL; Guo MZ
Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318
[TBL] [Abstract][Full Text] [Related]
13. Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma.
Pyo JS; Kang G; Kim DH; Chae SW; Park C; Kim K; Do SI; Lee HJ; Kim JH; Sohn JH
Pathol Res Pract; 2013 Apr; 209(4):228-32. PubMed ID: 23528368
[TBL] [Abstract][Full Text] [Related]
14. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
15. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
17. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
18. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
20. Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.
Zhao Z; Herman JG; Brock MV; Sheng J; Zhang M; Liu B; Guo M
PLoS One; 2014; 9(11):e112336. PubMed ID: 25375359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
